Drug for preventing or treating choriodal neovascular

A technology of neovascularization and choroid, applied in drug combinations, cardiovascular system diseases, sensory diseases, etc., can solve problems such as nintedanib not found

Inactive Publication Date: 2017-06-30
REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no report was found on nintedanib in the prevention or treatment of choroidal neovascularization

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for preventing or treating choriodal neovascular

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0041] Inhibitory effect of nintedanib ethanesulfonate administered orally for 23 days on choroidal neovascularization in rats

[0042] There were 20 BN rats, half male and half male. Fundus laser photocoagulation was performed on both eyes of the experimental animals on day zero (D0) to induce choroidal neovascularization (CNV). Eight days after laser photocoagulation (D8), animals with similar average fluorescence leakage scores of the laser spots on the fundus were selected and randomly divided into groups, with 4 animals in each group, half male and half male.

[0043] The animals in the model group (group 1) were not treated, the animals in the positive control group (group 2) were injected with Conbercept once into the vitreous, and the low-dose group (group 3) was given a dose of 8 mg / kg of the test product. The medium-dose group (group 4) was given a dose of 40 mg / kg of the test product, and the high-dose group (group 5) was given a dose of 200 mg / kg of the test produc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a drug for preventing or treating choriodal neovascular. The drug comprises active ingredients which are one or more of Nintedanib and salts thereof or solvate. The Nintedanib and salts thereof or solvate can prevent or treat choriodal neovascular. The drug has remarkable efficacy on preventing or treating choriodal neovascular when the oral dosage is 1.26-32mg / person per time.

Description

technical field [0001] The invention relates to a medicine for preventing or treating choroidal neovascularization. Background technique [0002] Choroidal neovascularization refers to proliferating blood vessels from the choroidal capillaries that extend through breaks in Bruch's membrane, between Bruch's membrane and the retinal pigment epithelium, or between the neural retina and the retinal pigment epithelium, or between the retinal pigment epithelium and the choroid Many diseases involving the RPE-Bruch's membrane-choriocapillary complex can lead to the formation of CNV, also known as subretinal neovascularization. More common in the macula, thus impairing central vision. This disease has become one of the main causes of blindness. Commonly seen in adult eyes, especially those over 60 years old. Numerous disease processes affect the retinal pigment epithelium-Bruch's membrane-choroidal capillaries, often accompanied by subretinal neovascularization. An example is ag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/496A61P27/02A61P9/10
CPCA61K31/496
Inventor 姚宗仁郭树华张佳春
Owner REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap